Navigation Links
TeamStaff Sells Per Diem Business Unit
Date:1/30/2008

ravel allied healthcare professionals. TeamStaff Rx operates throughout the U.S. and specializes in the supply of travel allied medical employees and travel nurses typically placed on 13 week assignments. TeamStaff's RS Staffing Services subsidiary specializes in providing medical and office administration/technical professionals through nationwide Federal Supply Schedule contracts with both the United States General Services Administration and the United States Department of Veterans Affairs. For more information, visit the TeamStaff web site at http://www.teamstaff.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

This press release contains "forward-looking statements" as defined by the Federal Securities Laws. Statements in this press release regarding TeamStaff, Inc.'s business, which are not historical facts are "forward-looking statements" that involve risks and uncertainties. TeamStaff's actual results could differ materially from those described in such forward-looking statements as a result of certain risk factors and uncertainties, including but not limited to: our ability to recruit and retain qualified temporary and permanent healthcare professionals and administrative staff upon acceptable terms; our ability to enter into contracts with hospitals, healthcare facility clients, affiliated healthcare networks, physician practice groups, government agencies and other customers on terms acceptable to us and to secure orders related to those contracts; changes in the timing of customer orders for placement of temporary and permanent healthcare professionals and administrative staff; the overall level of demand for our services; our ability to successfully implement our strategic growth, acquisition and integration strategies; the effect of existing or future government legislation and regulation; the loss of key officers and management personnel that cou
'/>"/>

SOURCE TeamStaff, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations
2. TeamStaff Receives Nasdaq Determination Letter
3. TeamStaff Receives A Letter of Reprimand From Nasdaq; No Further Action Contemplated
4. Turnaround Partners Sells Minority Ownership in Interactive Nutrition to Natural Nutrition
5. Informed Medical Communications Sells Consumer Internet Division to Revolution Health
6. Dragon Sells EPO Business; Focus on Antibiotic Core Business
7. NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
8. Celebrity Seating Only! Levitz Chair Signed by 39 Daytime Stars Sells for $1200 on Charitybuzz.com
9. Perdue AgriBusiness Announces Low Linolenic Soybean Contracting Opportunities with DuPont Business Pioneer Hi-Bred
10. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
11. MEDEX / Harvard Partnership Now Offers Affordable, New Intelligence to Individual Business & Leisure Travelers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...enter and Children's Medical Center Dallas say tha... muscle fibers// that are affected by cancer. The ...cer develops. It could also offer clues in search ...animal model system shown that new cells can be ge...
...c people and the possible link between these chang...the Wake Forest University School of Medicine// . ...e diagnosed with schizophrenia or bipolar disorder... be done by the team under a 5-year $1.1 million ...
...y that the media is insensitive to the disease and... "I have come across journalists refusing to sha...t even look at my eyes during interview sessions. ...p in breaking the stigma," said Vanlalmuana, the p...
...ht social stigma, HIV carriers in Jharkhand have f...r People Living with HIV has 200 members. More are...le to treat HIV carriers in a humane manner. It wi...nment to ensure adequate healthcare facilities and...
Other Medicine News:Health News:Cancer Affects Mature Muscle Fibers 2Health News:Brain changes in schizophrenia to be analyzed 2Health News:Brain changes in schizophrenia to be analyzed 3
(Date:9/3/2008)...and GENEVA, Sept. 3 /- Artelis SA and... based monoclonal antibody,production with the ach...per liter. This record level was accomplished by a...high-performance stable Selexis CHO,production cel...tists at,Selexis SA using their proprietary Selexi...
(Date:9/3/2008)...ny to Discuss Phase 3 Plans with FDA, PRINCETON, ...Inc.,announced today that it successfully complet...he company,s new, innovative low-dose, once-weekly... by its internal product,code AG-200-15. The Phase...,primary endpoint of ovulation suppression, cycle ...
(Date:9/3/2008)...uated in Repeat-Dosing Study in Subjects with ALS,... -- Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) ann... trial (SB-509-801) to evaluate its drug, SB-509, ...motor-neuron disease for which there,are limited t...-509, is an injectable formulation of a plasmid,en...
(Date:9/2/2008)... /-, - This Analysis Showe...of Stroke by 34% in Patients With Atrial Fibrillat...y Antithrombotic Therapy, The results of a post-h... presented today at the clinical trial update sess... 2008, in Munich, Germany. Previous results,from t...
Breaking Medicine Technology:Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Biotage Launches New 24 Well Pyrosequencing 28R 29 System 4286 1Biotage Launches New 24 Well Pyrosequencing 28R 29 System 4286 2Turn that frown upside down healthy gums are something to smile about 15548 1Turn that frown upside down healthy gums are something to smile about 15548 2Scientists 3A New technique identifies molecular biomarkers for disease 15546 1Scientists 3A New technique identifies molecular biomarkers for disease 15546 2Scientists 3A New technique identifies molecular biomarkers for disease 15546 3Ohio Faith Leaders Call on Sen Voinovich to Cosponsor Legislation to Protect Kids From Tobacco 15544 1Ohio Faith Leaders Call on Sen Voinovich to Cosponsor Legislation to Protect Kids From Tobacco 15544 2
...ous administration show potential for,new option t...e 04, 2007 /PRNewswire-FirstCall/ -- Millennium,Ph...on of positive,data for VELCADE, the market-leadin...who have received at least one prior therapy.,Thes...ubcutaneous,(SC) administration of VELCADE, a new ...
... With Follicular Lymphoma Reported,Today at ASCO A...wire/ -- GlaxoSmithKline plc,announced today long-...le one-week course of frontline treatment with the...dine I-131 Tositumomab) in,76 patients with newly ...ma (NHL). This regimen was found to induce durable...
Other Medicine Technology:New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 78-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
...nd medium volume laboratories, as well as specialt...simplicity and flexibility needed to respond to mu... the Elecsys 1010 system enables operators to hand...e testing without sacrificing ease of operation or...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t
...stry System provides high-performance detection te...c proteins and therapeutic drugs. It also delivers...ow the laboratory to streamline its operations and...esign enables numerous functions to be performed s...
The Embla 384 cell washer is a top-loading, robotic-compatible microplate washer for high throughput screening. It is designed specifically for cell-based assays, which require a gentler wash, but ca
Medicine Products: